Resmetirom therapy

Phase 3

Resmetirom therapy is one of 6 therapeutic programs targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Not yet recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 3

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 2

1 2

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 2

1 3

Resmetirom therapy

CCity University of New York

Phase 3

1 4

Pemvidutide

Altimmune

Phase 3

1 5

ALN-HSD

Alnylam Pharmaceuticals

Phase 2

1 6

CS060380

CCascade Pharmaceuticals, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

ApprovedNot yet recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NCT07680478

Clinical

Trials by Indication[1]

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

Assessing Nutrition-aligned Resmetirom Roll-out

Not yet recruiting·CCity University of New York·Approved·NCT07680478·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Resmetirom therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Resmetirom therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — City University of New York company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: CCity University of New York

Resmetirom therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

References

Drug Info

Quick Facts

Related News